Can fluoxetine's diminished efficacy in pediatric depression be explained by study sites, baseline severity, age, and psychological interventions? A secondary exploratory meta-regression.
Martin Plöderl, Richard Lyus, Florian Naudet
✦ AI-curated · Sources linked
In 30 seconds
This meta-analysis explored factors potentially explaining the declining efficacy of fluoxetine in pediatric depression, focusing on study site number, age, baseline severity, and psychological interventions. The analysis revealed that while the number of study sites increased, it was associated with decreased efficacy (B=1.57, p=0.02) and greater placebo response, though these results were influenced by a high-risk bias trial. Other factors did not significantly impact outcomes.
Key findings
- Increased number of study sites was associated with decreased efficacy (B=1.57, p=0.02).
- Greater placebo response was linked to the number of study sites (B=-1.90, p=0.01).
- Age, baseline severity, and psychological interventions did not significantly affect fluoxetine efficacy.
Why it matters
Understanding the factors influencing fluoxetine's efficacy in pediatric depression is crucial for clinicians to interpret treatment outcomes and guide therapeutic decisions. The findings suggest that trial characteristics may not significantly impact efficacy, challenging assumptions about treatment effectiveness.
What to keep in mind
The analysis may be affected by ecological fallacy regarding age and baseline severity, and results were influenced by a high-risk bias trial.